The Growth Hormone-insulin-like Growth Factor-I Axis in the Diagnosis and Treatment of Growth Disorders

Overview

Journal Endocr Connect

Specialty Endocrinology

Date 2018 May 5

PMID 29724795

Citations 52

Authors

Werner F Blum

Abdullah Alherbish

Afaf Alsagheir

Ahmed El Awwa

Walid Kaplan

Ekaterina Koledova

Martin O Savage

Affiliations

Soon will be listed here.

Abstract

The growth hormone (GH)-insulin-like growth factor (IGF)-I axis is a key endocrine mechanism regulating linear growth in children. While paediatricians have a good knowledge of GH secretion and assessment, understanding and use of measurements of the components of the IGF system are less current in clinical practice. The physiological function of this axis is to increase the anabolic cellular processes of protein synthesis and mitosis, and reduction of apoptosis, with each being regulated in the appropriate target tissue. Measurement of serum IGF-I and IGF-binding protein (IGFBP)-3 concentrations can complement assessment of GH status in the investigation of short stature and contribute to prediction of growth response during GH therapy. IGF-I monitoring during GH therapy also informs the clinician about adherence and provides a safety reference to avoid over-dosing during long-term management.

Citing Articles

IGF-1 Assessment During Weekly Somatrogon Treatment in Pediatric Patients With GH Deficiency.

Nayak S, Wajnrajch M, Korth-Bradley J, Taylor C, Thomas M, Maniatis A J Endocr Soc. 2025; 9(2):bvaf001.

PMID: 39872400 PMC: 11770336. DOI: 10.1210/jendso/bvaf001.

Baseline Clinical Factors Associated with Cessation of Growth Hormone Therapy in Patients with Severe Growth Hormone Deficiency - Real World Evidence.

Nadarajah N, Ssemmondo E, Brooks S, Akinyombo R, Adeleke K, Deshmukh H Int J Endocrinol Metab. 2025; 22(3):e147825.

PMID: 39839805 PMC: 11742744. DOI: 10.5812/ijem-147825.

Expression of the IGF‑1Ea isoform in human placentas from third trimester normal and idiopathic intrauterine growth restriction singleton pregnancies: Correlations with clinical and histopathological parameters.

Fasoulopoulos A, Varras M, Varra F, Philippou A, Myoteri D, Varra V Mol Med Rep. 2025; 31(3.

PMID: 39791214 PMC: 11751665. DOI: 10.3892/mmr.2025.13434.

Case report: Duplication of the gene is a novel cause of nesidioblastosis: evidence from a case with Silver-Russell syndrome-like phenotype related to chromosome 7.

Shoji T, Yamauchi I, Kawasaki H, Iwanaga K, Hakata T, Tanaka D Front Endocrinol (Lausanne). 2024; 15:1431547.

PMID: 39720245 PMC: 11666348. DOI: 10.3389/fendo.2024.1431547.

Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin.

Yuen K, Hjortebjerg R, Ganeshalingam A, Clemmons D, Frystyk J Front Endocrinol (Lausanne). 2024; 15():1456195.

PMID: 39665021 PMC: 11632222. DOI: 10.3389/fendo.2024.1456195.

References

Yakar S, Rosen C, Beamer W, Ackert-Bicknell C, Wu Y, Liu J . Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002; 110(6):771-81. PMC: 151128. DOI: 10.1172/JCI15463. View

Savage M, Backeljauw P, Calzada R, Cianfarani S, Dunkel L, Koledova E . Early Detection, Referral, Investigation, and Diagnosis of Children with Growth Disorders. Horm Res Paediatr. 2016; 85(5):325-32. DOI: 10.1159/000444525. View

. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000; 85(11):3990-3. DOI: 10.1210/jcem.85.11.6984. View

Wit J, Ranke M, Albertsson-Wikland K, Carrascosa A, Rosenfeld R, Buuren S . Personalized approach to growth hormone treatment: clinical use of growth prediction models. Horm Res Paediatr. 2013; 79(5):257-70. DOI: 10.1159/000351025. View

Secco A, Di Iorgi N, Napoli F, Calandra E, Ghezzi M, Frassinetti C . The glucagon test in the diagnosis of growth hormone deficiency in children with short stature younger than 6 years. J Clin Endocrinol Metab. 2009; 94(11):4251-7. DOI: 10.1210/jc.2009-0779. View

Ranke M, Lindberg A . Predicting growth in response to growth hormone treatment. Growth Horm IGF Res. 2008; 19(1):1-11. DOI: 10.1016/j.ghir.2008.08.001. View

Hawkes C, Grimberg A . Insulin-Like Growth Factor-I is a Marker for the Nutritional State. Pediatr Endocrinol Rev. 2016; 13(2):499-511. PMC: 5576178. View

Fazeli P, Klibanski A . Determinants of GH resistance in malnutrition. J Endocrinol. 2013; 220(3):R57-65. PMC: 3994591. DOI: 10.1530/JOE-13-0477. View

Schonau E, Westermann F, Rauch F, Stabrey A, Wassmer G, Keller E . A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. Eur J Endocrinol. 2001; 144(1):13-20. DOI: 10.1530/eje.0.1440013. View

10.

Blum W, Breier B . Radioimmunoassays for IGFs and IGFBPs. Growth Regul. 1994; 4 Suppl 1:11-9. View

11.

Juul A, Bernasconi S, Clayton P, Kiess W, DeMuinck-Keizer Schrama S . European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency. Horm Res. 2002; 58(5):233-41. DOI: 10.1159/000066265. View

12.

Storr H, Prasad R, Temple I, Metherell L, Savage M, Walker J . Heterogeneity of the growth phenotype and birth size in acid-labile subunit (ALS) deficiency. J Endocrinol Invest. 2014; 38(4):407-12. DOI: 10.1007/s40618-014-0195-1. View

13.

Ranke M . Insulin-like growth factor binding-protein-3 (IGFBP-3). Best Pract Res Clin Endocrinol Metab. 2015; 29(5):701-11. DOI: 10.1016/j.beem.2015.06.003. View

14.

Blum W, Ranke M, Kietzmann K, Gauggel E, Zeisel H, BIERICH J . A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab. 1990; 70(5):1292-8. DOI: 10.1210/jcem-70-5-1292. View

15.

Friedrich N, Wolthers O, Arafat A, Emeny R, Spranger J, Roswall J . Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab. 2014; 99(5):1675-86. DOI: 10.1210/jc.2013-3060. View

16.

Courtland H, Sun H, Beth-On M, Wu Y, Elis S, Rosen C . Growth hormone mediates pubertal skeletal development independent of hepatic IGF-1 production. J Bone Miner Res. 2010; 26(4):761-8. PMC: 3179330. DOI: 10.1002/jbmr.265. View

17.

. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl. 2006; 450:76-85. DOI: 10.1111/j.1651-2227.2006.tb02378.x. View

18.

Blum W, Ranke M, BIERICH J . A specific radioimmunoassay for insulin-like growth factor II: the interference of IGF binding proteins can be blocked by excess IGF-I. Acta Endocrinol (Copenh). 1988; 118(3):374-80. DOI: 10.1530/acta.0.1180374. View

19.

Sisley S, Vargas Trujillo M, Khoury J, Backeljauw P . Low incidence of pathology detection and high cost of screening in the evaluation of asymptomatic short children. J Pediatr. 2013; 163(4):1045-51. PMC: 3786014. DOI: 10.1016/j.jpeds.2013.04.002. View

20.

Meinhardt U, Ho K . Modulation of growth hormone action by sex steroids. Clin Endocrinol (Oxf). 2006; 65(4):413-22. DOI: 10.1111/j.1365-2265.2006.02676.x. View